Home / Market News / $PCVX
benzinga Corporate Catalyst Impact 55/100 ● positive

Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125

Oct 5, 2026, 12:53 PM UTC · Primary ticker $PCVX

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Vaxcyte (PCVX) and increased the price target from $116 to $125. This indicates a positive outlook from a prominent analyst, which could lead to increased investor confidence and short-term upward price movement for Vaxcyte.

Guggenheim analyst Seamus Fernandez maintained a Buy rating on Vaxcyte and raised the price target from $116 to $125. This action signals a strengthened conviction in Vaxcyte's future performance by a reputable financial institution. For traders, this could translate into short-term buying interest and a potential upward bump in the stock price as investors react to the positive analyst sentiment. The long-term implications depend on Vaxcyte's actual performance and pipeline developments, but this analyst upgrade provides a positive near-term catalyst. The key opportunity for traders is to capitalize on the immediate positive sentiment following the price target increase.

$PCVX positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.